Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny study hints arm cuff may shield heart during attack

NCT ID NCT07272408

Knowledge-focused Sponsor: Helwan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether briefly restricting blood flow to an arm (remote ischemic conditioning) before opening a blocked heart artery could reduce heart damage. Only 2 patients took part, so the results are not meaningful. The study looked at heart function, kidney problems, and survival, but no firm conclusions can be drawn.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
remote ischemic conditioning (a procedure using brief blood flow restriction to an arm or leg)
What this could lead to
If this approach shows benefit in larger trials, it could point toward a simple, low-cost way to reduce heart damage during a heart attack.
What could go wrong
This trial enrolled only 2 people, so the findings are not reliable. Larger studies are needed to know if it works or if there are risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

2 people

The number who actually took part.

Started

Sep 2022

Finished

Dec 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age more than 18 and less than 75 years old. * Both sexes. * Patients with new ST-segment elevation at the J-point in V1:V6 leads with the cut-point: ≥ 1mm other than leads V2-V3 where the following cut-points apply: ≥ 2mm in men ≥ 40 years; ≥ 2.5mm in men \< 40 years, or ≥ 1.5mm in women regardless of age. * Patients with new left bundle branch block (LBBB). Exclusion Criteria: * ST-segment elevation myocardial infarction (STEMI) with cardiogenic shock. * Severe comorbidities (uncontrolled hypertension, morbid obesity, recent cerebrovascular stroke, respiratory failure, sepsis, and stage 4 \& 5 malignancy). * End-stage renal disease on hemodialysis. * Previous coronary artery bypass graft surgery (CABG). * Myocardial infarct within the previous 30 days. * Multi-vessel coronary artery disease. * Failure of culprit vessel recanalization. * Conditions precluding use of remote conditioning ie: paresis of upper limb. * Life expectancy of less than 1 year due to a non-cardiac pathology. * Patients who receive nephrotoxic drugs such as non-steroidal anti-inflammatory drugs and aminoglycosides.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ischemic conditioning are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ischemic conditioning Primary percutaneous coronary intervention REMOTE

Contacts and locations

Locations

  • Helwan University

    Helwan, 11795, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.